Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...

Ebenbuild GmbH, a Munich-based deep-tech healthcare company, today announced the publication of a peer-reviewed ...

Cautionary Language Concerning Forward-Looking Statements ...

MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, ...

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...

The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis ...